TP53 mutations in human cancers: origins, consequences, and clinical use

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Somatic TP53 gene mutations are frequent in human cancers.
• Germline TP53 mutations cause Li-Fraumeni syndrome, increasing early-onset cancer risk.
• TP53 mutations are diverse, offering insights into cancer etiology and mutagenic mechanisms.

Purpose of the Study:

• To summarize current knowledge on TP53 gene variations in human cancers and populations.
• To review the clinical applications of TP53 mutation knowledge.
• To highlight the utility of the IARC TP53 Database and the Hupki mouse model.

Main Methods:

• Compilation of TP53 mutations from the IARC TP53 Database.
• Analysis of mutation types and distribution in human cancers.
• Review of existing literature on TP53 gene variations and clinical applications.
• Utilizing the Hupki mouse model for mutagenesis studies.

Main Results:

• TP53 mutations are predominantly single-base substitutions across the coding sequence.
• Mutation patterns can indicate underlying mutagenic mechanisms in cancer development.
• TP53 mutations serve as prognostic and predictive markers in oncology.
• The IARC TP53 Database and Hupki mouse model are valuable resources.

Conclusions:

• Understanding TP53 gene variations is crucial for cancer research and treatment.
• TP53 mutations have significant implications for cancer prognosis, prediction, and therapy.
• Continued research into TP53 variations will advance personalized cancer medicine.